FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 442 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR 3-in-1 Approach Helps Women in Rural Areas Get Cancer Screenings June 1, 2023 New Treatments for Non-Small Cell Lung Cancer With an EGFR Mutation:... December 16, 2021 Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients... July 9, 2026 Sotorasib in Combination with Panitumumab Results in Longer PFS in Patients... December 6, 2023 Load more HOT NEWS Immunotherapy’s Skin Side Effects: Are Microbes to Blame? Cancer.Net’s 20th Anniversary: Celebrating Our Mission of Providing Trustworthy Cancer Information Cancer Survivor Kicked Out Of Bridal Party Cause She Refused To... FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer...
